Antengene Corporation Limited (HK:6996)
:6996
Want to see HK:6996 full AI Analyst Report?
6996 Stock Chart & Stats
HK$5.27
HK$0.00(0.00%)
At close: 4:00 PM EST
HK$5.27
HK$0.00(0.00%)
Day’s Range― - ―
52-Week RangeHK$2.68 - HK$8.16
Previous CloseN/A
Volume1.25M
Average Volume (3M)1.88M
Market Cap
HK$2.89B
Enterprise ValueHK$1.94B
Total Cash (Recent Filing)HK$734.29M
Total Debt (Recent Filing)HK$257.51M
Price to Earnings (P/E)―
Beta2.25
Next Earnings
Aug 21, 2026EPS Estimate
0.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.38
Shares Outstanding679,446,660
10 Day Avg. Volume1,689,397
30 Day Avg. Volume1,876,149
Financial Highlights & Ratios
PEG Ratio0.35
Price to Book (P/B)3.32
Price to Sales (P/S)20.24
P/FCF Ratio-11.92
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$9.60Price Target Upside82.16% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.37
Revenue Forecast (FY)HK$703.70M
Bulls Say, Bears Say
Bulls Say
Improving Revenue GrowthA materially stronger top-line in 2025 signals improving commercial traction in core Asian markets and better product adoption. Sustained revenue growth supports scale for R&D and commercialization, reducing per-unit costs and improving the odds of reaching self-funded operations over time.
High Gross MarginsA 65% gross margin indicates strong product-level economics and pricing power for its oncology portfolio. Durable, above-average gross margins create scope to fund SG&A and R&D while moving toward operating leverage as revenue scales, underpinning long-term profitability potential.
Low And Improving LeverageModest and declining leverage preserves financial optionality for a capital-intensive biotech. Low debt reduces near-term default and interest burdens, enabling management to prioritize R&D and commercialization choices and access equity or partnership funding from a position of relative strength.
Bears Say
Persistent Net LossesSustained operating and net losses erode capital and limit internal reinvestment capacity. Until the company produces sustained positive operating income, it will remain dependent on external financing or partnerships, which can dilute shareholders and constrain strategic flexibility over the medium term.
Negative Free Cash FlowPersistent negative free cash flow forces reliance on existing capital, partner milestones, or new financing to fund operations and trials. Even with improving trends, continued cash burn raises dilution and execution risk, limiting the company's ability to finance new programs organically in 2–6 months.
Eroding Equity And Poor ROEDeclining equity and a deeply negative ROE signal capital erosion from unprofitable operations. This weakens the firm’s balance-sheet resilience, increases probability of future equity raises or restructuring, and reduces long-term shareholder value unless profitability is restored.
Antengene Corporation Limited News
6996 FAQ
What was Antengene Corporation Limited’s price range in the past 12 months?
Antengene Corporation Limited lowest stock price was HK$2.68 and its highest was HK$8.16 in the past 12 months.
What is Antengene Corporation Limited’s market cap?
Antengene Corporation Limited’s market cap is HK$2.89B.
When is Antengene Corporation Limited’s upcoming earnings report date?
Antengene Corporation Limited’s upcoming earnings report date is Aug 21, 2026 which is in 92 days.
How were Antengene Corporation Limited’s earnings last quarter?
Antengene Corporation Limited released its earnings results on Mar 20, 2026. The company reported -HK$0.3 earnings per share for the quarter, the consensus estimate of -HK$0.3 by HK$0.
Is Antengene Corporation Limited overvalued?
According to Wall Street analysts Antengene Corporation Limited’s price is currently Undervalued.
Does Antengene Corporation Limited pay dividends?
Antengene Corporation Limited does not currently pay dividends.
What is Antengene Corporation Limited’s EPS estimate?
Antengene Corporation Limited’s EPS estimate is 0.41.
How many shares outstanding does Antengene Corporation Limited have?
Antengene Corporation Limited has 679,446,660 shares outstanding.
What happened to Antengene Corporation Limited’s price movement after its last earnings report?
Antengene Corporation Limited reported an EPS of -HK$0.3 in its last earnings report, expectations of -HK$0.3. Following the earnings report the stock price went up 0.247%.
Which hedge fund is a major shareholder of Antengene Corporation Limited?
Currently, no hedge funds are holding shares in HK:6996
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Antengene Corporation Limited
Antengene Corporation Limited (6996) is a biotechnology company focused on the discovery, development, and commercialization of innovative therapies for cancer treatment. The company operates primarily in the biopharmaceutical sector, concentrating on the development of monoclonal antibodies, small molecules, and other biologics aimed at addressing unmet medical needs in oncology. Antengene's core products include a pipeline of drug candidates designed to target various cancers, with efforts in both domestic and international markets.
6996 Stock 12 Month Forecast
Average Price Target
HK$9.60
▲(82.16% Upside)
Technical Analysis
Innovent Biologics
―
Alphamab Oncology
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
CStone Pharmaceuticals
―
Ascentage Pharma Group International
―
Options Prices
Currently, No data available
---